Loading
companiesCompany
GeneQuantum Healthcare (Suzhou)
GeneQuantum Healthcare (Suzhou) is a China-based biotechnology company running 2 late-stage cancer trials of GQ1005 and phase II in HER2-positive breast cancer.
Also called: GeneQuantum Healthcare (Suzhou) Co., Ltd.
Overview
GeneQuantum Healthcare (Suzhou), based in Suzhou, China, is a biotechnology company. GeneQuantum Healthcare develops bioconjugate therapeutics, including antibody-drug conjugates, using proprietary site-specific conjugation technologies. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials (1 in phase 3), testing GQ1005 and phase II in HER2-positive breast cancer. The largest, NCT06464055 (A Study of GQ1010 in Subjects With Advanced Solid Tumours), plans to enrol 260 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Suzhou, CN
Scorecard
All companies#392of 1244 companies, score 9
- phase 3 +3
- targets +2
- modalities +2
- registry trials +2
0 approved, 1 in phase 3, 0 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
Stage
Growth stage
Website
Founded
2013
Phase 3ADC
GQ1005 is an experimental antibody-drug conjugate from GeneQuantum Healthcare (Suzhou) in phase 3 trials for HER2-positive breast cancer, aimed at HER2.